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Abstract	
Context:	Bladder	cancer	(BC)	is	a	significant	health	problem,	and	understanding	
the	risk	factors	for	this	disease	could	improve	prevention	and	early	detection.	
Objective:	To	provide	a	systematic	review	and	summary	of	novel	developments	
in	epidemiology	and	risk	factors	for	BC.	
Evidence	acquisition:	A	systematic	review	of	original	articles	was	performed	by	
two	pairs	of	reviewers	(M.G.C.,	I.J.,	F.E.,	and	K.P.)	using	PubMed/Medline	in	
December	2017,	updated	in	April	2018.	To	address	our	primary	objective	of	
reporting	contemporary	studies,	we	restricted	our	search	to	include	studies	from	
the	last	5	yr.	We	subdivided	our	review	according	to	specific	risk	factors	(PICO	
[Population	Intervention	Comparator	Outcome]).	
Evidence	synthesis:	Our	search	found	2191	articles,	of	which	279	full-text	
manuscripts	were	included.	We	separated	our	manuscripts	by	the	specific	risk	
factor	they	addressed	(PICO).	According	to	GLOBOCAN	estimates,	there	were	
430	000	new	BC	cases	and	165	000	deaths	worldwide	in	2012.	Tobacco	smoking	
and	occupational	exposure	to	carcinogens	remain	the	factors	with	the	highest	
attributable	risk.	The	literature	was	limited	by	heterogeneity	of	data.	
Conclusions:	Evidence	is	emerging	regarding	gene-environment	interactions,	
particularly	for	tobacco	and	occupational	exposures.	In	some	populations,	
incidence	rates	are	declining,	which	may	reflect	a	decrease	in	smoking.	
Standardisation	of	reporting	may	help	improve	epidemiologic	evaluation	of	risk.		
Patient	summary:	Bladder	cancer	is	common	worldwide,	and	the	main	risk	
factors	are	tobacco	smoking	and	exposure	to	certain	chemicals	in	the	working	
and	general	environments.	There	is	ongoing	research	to	identify	and	reduce	risk	
factors,	as	well	as	to	understand	the	impact	of	genetics	on	bladder	cancer	risk.	
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1.	Introduction	
Bladder	cancer	(BC)	is	the	ninth	most	common	cancer	worldwide	with	a	yearly	
incidence	of	approximately	430	000	cases	[1],	and	it	ranks	13th	in	terms	of	
yearly	mortality	from	cancer	[1].	There	is	a	male	predominance,	and	it	is	the	
seventh	most	common	cancer	worldwide	in	men	[2].	In	the	USA,	BC	is	the	fourth	
most	common	cancer	in	men	[3].	BC	is	a	cancer	of	industrialized	nations	with	an	
age-standardized	incidence	rate,	which	is	three-fold	greater	in	high-resource	
versus	low-resource	countries	[4].	The	highest	incidence	rates	are	in	North	
America,	Europe,	and	parts	of	Western	Asia.	However,	mortality	rates	are	
greater	in	developing	regions	[5].		
Urothelial	BC	is	the	most	common	subtype.	Approximately	75%	of	patients	
present	with	non–muscle-invasive	disease,	confined	to	the	bladder	
mucosa/submucosa.	This	stage	is	usually	managed	with	local	treatment	and	
surveillance,	and	has	a	particularly	high	prevalence	due	to	the	nonaggressive	
natural	history	of	this	disease	[6].	The	remaining	25%	have	muscle-invasive	
disease	and	often	undergo	cystectomy,	multimodal	therapy	(transurethral	
resection,	chemotherapy,	and	radiation	therapy),	or	palliation	[7].	
In	2013,	Burger	et	al	[8]	published	a	detailed	review	on	the	epidemiology	of	BC	
and	its	risk	factors.	In	our	work,	we	have	searched	contemporary	series	to	
compile	a	current-day	picture	of	BC	epidemiology,	and	provide	a	discussion	of	
further	work	that	is	needed	to	impact	environmental	causes	of	BC.	
	
2.	Evidence	acquisition	
A	systematic	review	of	original	articles	was	performed	using	PubMed/Medline	in	
December	2017	and	again	in	April	2018.	We	used	the	following	search	terms	
(Fig.	1):	((Bladder	cancer	[MeSH	terms]	and	incidence	[MeSH	terms])	(OR)	
(Bladder	cancer	[MeSH	terms]	and	prevalence	[MeSH])	(OR)	(Bladder	cancer	
[MeSH	terms]	and	risk)	(OR)	(Bladder	cancer	[MeSH	terms]	and	risk	factor	
[MeSH	terms])	(OR)	Bladder	cancer	[MeSH	terms]	and	hazard)).	Manuscripts	
were	excluded	if	they	were	not	in	English,	had	<50	patients,	were	not	about	
humans,	and	were	not	published	since	2012.	Conference	abstracts	were	also	
excluded.	Two	pairs	of	reviewers	(M.G.C.,	I.J.,	F.E.,	and	K.P.)	reviewed	the	
abstracts	using	a	priori	exclusion/inclusion	criteria	and	Covidence	software	
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(Cochrane	Library).	Conflicts	were	resolved	between	the	authors	or	with	the	
involvement	of	a	senior	author.	Reference	lists	of	included	manuscripts	were	
also	searched.	Systematic	reviews	and	meta-analysis	were	included	because	our	
primary	objective	was	to	identify	significant/relevant	studies	that	had	been	
published	since	2012.		
We	report	our	findings	in	accordance	with	the	Preferred	Reporting	Items	for	
Systematic	Reviews	and	Meta-analyses	(PRISMA)	guidelines	(Supplementary	
Table	1)	[9].	The	review	was	a	priori	registered	with	the	PROSPERO	database.	
	
3.	Evidence	synthesis	
Our	search	found	2191	articles,	of	which	279	full-text	manuscripts	were	
included.	We	separated	our	manuscripts	by	the	specific	risk	factor	they	
addressed	(PICO	[Population	Intervention	Comparator	Outcome]),	for	example,	
tobacco	smoking	(Table	1)	[10].	
	
3.1.	Epidemiology,	incidence,	prevalence,	and	mortality	of	BC	
We	provide	an	overview	of	BC	incidence,	mortality,	and	prevalence	worldwide	
using	the	Cancer	Incidence	in	Five	Continents	Series	GLOBOCAN	2012	and	World	
Health	Organization	Mortality	databases	held	at	the	International	Agency	for	
Research	on	Cancer	[2,11,12],	as	well	as	other	studies	published	using	the	
databases	above.		
According	to	estimates,	there	were	430	000	new	BC	cases	and	165	000	deaths	
worldwide	in	2012	[2].	Three-quarters	of	new	cases	occurred	in	men,	with	
incidence	rates	in	men	being	consistently	higher	than	those	in	women	and	
male:female	ratios	varying	from	6:1	to	2:1	in	different	regions	worldwide	[2].	
The	risk	of	BC	increased	with	age,	with	age-specific	curves	increasing	steeply	
after	the	age	of	50	yr	[11].	A	particular	caveat	for	interpreting	geographical	
patterns	and	temporal	trends	of	BC	incidence	are	large	variations	in	diagnostic	
and	cancer	registration	practices	in	distinguishing	muscle-invasive	(MIBC)	and	
non–muscle-invasive	(NMIBC)	BC	[1,11].	Owing	to	inclusion	of	NMIBC	in	
reporting	and	the	fact	that	75%	of	newly	diagnosed	BCs	are	NMIBCs,	as	well	as	
the	fact	that	these	tumours	have	a	good	prognosis,	there	was	a	high	disease	
prevalence,	with	over	1.3	million	prevalent	cases	(5-yr	prevalence)	worldwide	
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[2].	Age-standardised	incidence	and	mortality	rates	varied	widely,	with	the	
highest	rates	occurring	in	Europe	and	North	America	as	well	as	some	countries	
in	Northern	Africa	and	Western	Asia,	while	the	lowest	rates	occurred	in	Latin	
America,	Sub-Saharan	Africa,	and	South	East	Asia	[1,2].	Figures	2	and	3	are	maps	
of	BC	incidence	and	mortality	rates	in	men	and	women	worldwide	[2].	
According	to	the	latest	observed	data	from	the	period	2008	to	2012	from	343	
registries	in	65	countries	published	in	CI5	Vol	XI,	age-standardised	BC	incidence	
rates	(world	standard	population)	in	men	varied	from	>30/100	000	in	cancer	
registries	in	Italy	and	Spain	to	<3/100	000	in	several	registries	from	India,	China,	
and	Sub-Saharan	Africa	[11].	Large	geographic	variations	reflect	differences	in	
exposures	to	known	risk	factors,	notably	smoking	prevalence,	occupational	
exposures,	and	Schistosoma	haematobium	infection	(the	latter	relevant	in	Africa	
and	Western	Asia	and	causing	squamous	cell	carcinoma,	otherwise	rare	in	the	
urinary	tract),	but	also	result	from	different	diagnostic	and	registration	practices	
[1,11].		
Overall,	BC	incidence	and	mortality	are	higher	in	higher-income	than	in	lower-
income	countries	[2,5].	Several	studies	have	explored	correlations	between	the	
Human	Development	Index	(HDI)	and	BC	incidence	and	mortality	[12,13].	The	
study	by	Greiman	et	al	[4]	showed	a	moderately	strong	inverse	correlation	(r	=	–
1.02,	r2	=	0.80)	between	HDI	and	mortality	to	incidence	ratio	(MIR),	thus	
indicating	increasing	survival	with	higher	HDI	levels.	MIR	was	further	shown	to	
be	higher	in	women	than	in	men	in	most	populations	worldwide,	which	could	
possibly	be	explained	by	sex-specific	differences	in	the	biology	of	the	disease,	
time	to	diagnosis,	treatment	decisions,	and	other	factors	[14].	
The	study	of	recent	international	trends	of	BC	incidence	and	mortality	by	Antoni	
et	al	[1]	reported	diverging	incidence	trends	with	decline	or	stabilisation	in	men	
versus	increases	in	women	observed	in	many	populations	worldwide.	In	
contrast,	mortality	rates	have	uniformly	been	decreasing	in	most	populations	
worldwide	(Fig.	4)	[1].		
Observed	global	geographical	patterns	and	temporal	trends	in	incidence	largely	
reflect	trends	in	smoking	prevalence,	even	if	other	factors,	such	as	S.	
haematobium	infection	and	occupational	exposures,	are	important	in	selected	
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populations.	Standardisation	of	practices	for	reporting	BC	in	cancer	registries	is	
necessary	to	improve	the	ability	to	compare	incidence	data	worldwide.			
	
3.2.	Risk	factors	for	BC	
3.2.1.	Smoking	
This	is	the	most	important	risk	factor	for	BC	with	an	attributable	risk	of	
approximately	50%	[15].	Tobacco	is	a	rich	source	of	known	carcinogenic	
compounds	such	as	aromatic	amines	and	N-nitroso	compounds	[16].	These	
compounds	result	in	DNA	damage	in	the	form	of	double-stranded	breaks,	base	
modifications,	and	bulky	adduct	formation	[16].	Such	genomic	events	are	
implicated	in	gene-smoking	interactions.		
The	strongest	support	for	the	association	of	tobacco	use	and	BC	is	a	meta-
analysis	of	83	studies,	in	which	the	pooled	relative	risk	(RR)	for	current	versus	
never	smokers	was	3.47	(95%	confidence	interval	[CI]	3.07–3.91)	and	for	ex-
smokers	2.04	(95%	CI	1.85–2.25)	[15].	The	lower	rate	for	former	smokers	
suggests	that	smoking	cessation	may	reduce	the	risk	for	BC	development	[17].	
The	meta-analysis	also	found	that	disease-specific	mortality	(DSM)	is	greater	in	
current	smokers	versus	ex-smokers	(1.53	[95%	CI	1.12–2.09])	and	1.44	[95%	CI	
0.99–2.11],	respectively).	Limitations	cited	by	the	authors	of	the	meta-analysis	
were	the	heterogeneity	with	which	smoking	histories	were	obtained	and	the	cut-
points	used	for	stratifying	smoking	intensities	and	durations.	This	is	important,	
as	there	is	strong	evidence	that	smoking	duration	and	intensity	are	positively	
correlated	with	an	increased	risk	of	BC	[18–21].	
BC	may	also	be	associated	with	opium	smoking.	Afshari	et	al	[22]	conducted	a	
meta-analysis	of	17	studies	and	found	an	odds	ratio	(OR)	of	3.85	(95%	CI	3.05–
4.87),	which	increased	in	magnitude	if	there	was	concomitant	tobacco	use.		
A	large	cohort	study	of	34	000	cannabis	smokers	in	California	[23]	found	no	
association	with	BC	over	an	11-yr	follow-up	period.	With	increased	legalisation	
of	cannabis	use	in	the	USA,	more	data	will	emerge	regarding	its	impact	on	BC	
rates.			
The	impact	of	e-cigarette	use	on	BC	risk	will	also	be	important	to	evaluate,	since	
there	is	evidence	for	similar	carcinogens	in	the	urine	of	e-cigarette	and	regular	
cigarette	users	[24].	
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Interestingly,	in	a	study	by	Westhoff	et	al	[25],	BC	survivors	often	have	little	idea	
of	what	may	have	caused	their	disease,	suggesting	an	increasing	need	for	
smoking	cessation	awareness.	
	
3.2.2.	Occupational	carcinogen	exposure	
We	found	20	articles	published	in	the	last	5	yr	on	occupational	BC.	The	largest	
study	was	by	Cumberbatch	et	al	[26],	which	reviewed	263	publications.	An	
increased	BC	incidence	was	seen	in	42/61	occupations	and	DSM	was	raised	in	
16/40	(not	all	studies	assessed	DSM).	The	highest	pooled	RR	was	in	tobacco	
workers	(RR	1.72	[95%	CI	1.37–2.15])	and	dye	workers	(RR	13.4	[95%	CI	1.5–
48.2]).	The	highest	pooled	DSM	RR	was	in	metal	workers	(10.2	[95%	CI	6.89–
15.09]).	Overall,	occupational	carcinogen	exposure	amounts	to	5–6%	of	the	
attributable-risk	of	BC	[25].		
A	limitation	of	occupational	risk	studies	is	that	often	there	is	exposure	
heterogeneity	in	the	classification	of	occupations.	There	are	classification	
systems	in	place	such	as	the	NYK	and	ISCO-1958	(Nordisk	Yrkesklassificering,	or	
Nordic	Occupational	Classification,	and	the	International	Standard	Classification	
of	Occupations);	however,	it	is	known	that	chemical	exposure	derives	from	the	
actual	“task”	that	is	being	conducted	within	a	workplace,	and	occupational	
classifications	may	group	individuals	who	have	different	exposures	to	bladder	
carcinogens	and	have	disparate	risk	profiles.	Furthermore,	not	all	studies	adjust	
for	smoking.	Agents	with	a	suspected/established	role	as	an	occupational	
bladder	carcinogen	include	2-naphthylamine,	4-aminobiphenyl,	toluene,	4,4’-
methylenebis(2-chloroaniline),	metal	working	fluids,	polyaromatic	
hydrocarbons	(PAH),	perchloroethylene,	and	diesel	exhaust	[26,27]	(Table	2).	
	
3.2.3.	Dietary	factors	
As	for	many	diseases,	BC	risk	has	been	investigated	for	dietary	factors.	We	found	
29	articles	reporting	a	link	with	BC	and	dietary	components.		
	
3.2.3.1.	Alcohol	
Whilst	some	small	reports	suggest	a	link	with	BC	risk	[28],	a	multicentre	
epidemiologic	study	(European	Prospective	Investigation	into	Cancer	and	
	 8	
Nutrition	[EPIC])	involving	476	160	persons	followed	up	over	13.9	yr	showed	no	
association	[29].	Those	who	reported	high	intake	have	an	increased	risk	of	BC,	
but	there	was	no	dose	response,	suggesting	possible	confounding	lifestyle	
factors.	No	increased	risk	was	observed	in	Asian	populations	with	a	deficient	
alcohol	dehydrogenase	enzyme	(this	metabolises	acetaldehyde	in	alcohol,	which	
may	be	carcinogenic)	[30].		
	
3.2.3.2.	Vitamins/antioxidants	
Several	large	recent	studies	evaluated	the	link	between	vitamins	and	
antioxidants	(such	as	flavonol,	lignans,	and	plasma	carotenoids)	and	BC	[31,32].	
These	agents	are	thought	to	possess	anticarcinogenic	properties	and	are	
excreted	in	the	urine.	Animal	studies	have	suggested	a	protective	role,	but	two	
meta-analyses	in	our	search	reported	conflicting	results	[33,34].	A	meta-analysis	
of	seven	(two	cohort	and	five	case-control)	studies	suggested	that	a	pooled	RR	
for	the	lowest	category	versus	the	highest	category	of	vitamin	D	was	1.34	(95%	
CI	1.17–1.53)	[35].	The	limitation	is	the	use	of	different	criteria	for	vitamin	D	
deficiency.	Furthermore,	a	meta-analysis	of	five	(two	cohort	and	three	case-
control)	studies	demonstrated	a	protective	effect	of	a	high	serum	vitamin	D	level	
on	BC	risk	(RR 0.75,	95%	CI	0.65–0.87)	[36].	
	
3.2.3.3.	Dietary	fluid	consumption	
Drinking	coffee	was	recently	evaluated	by	the	International	Agency	for	Research	
on	Cancer	(IARC)	Cancer	Monographs	Working	Group	as	“unclassifiable	as	to	its	
carcinogenicity	to	humans”	(group	3).	They	reviewed	10	cohort	and	several	case-
control	studies	from	Europe,	the	USA,	and	Japan,	and	found	no	consistent	
evidence	of	association	between	drinking	coffee	and	BC	[37].	
A	meta-analysis	of	24	(six	cohort	and	18	case-control)	studies	found	no	
association	between	BC	incidence	and	consumption	of	tea	[38],	cola,	
decaffeinated	or	energy	drinks	[39],	or	dairy	products	[40].	Some	argue	that	
higher	levels	of	hydration	may	reduce	BC	incidence	by	diluting	carcinogen	
contact	with	the	urothelium	and	promoting	more	frequent	voiding	of	urine,	but	
no	significant	link	has	been	established	[41–43].	However,	due	to	the	possible	
presence	of	disinfection	by-products	(chlorination),	some	authors	have	cited	an	
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increased	BC	risk	with	elevated	tap	water	consumption	due	to	the	presence	of	
trihalomethanes	[43,44].	
	
3.2.3.4.	Fruits	and	vegetables	
There	is	no	consensus	on	the	attributable	risk	from	dietary	components.	
Generally,	the	data	are	conflicting.	However,	a	meta-analysis	of	15	prospective	
cohort	studies	showed	a	summary	RR	for	an	increase	of	one	serving	per	day	of	
0.97	(95%	CI	0.95–0.99)	for	vegetables	and	fruits	[45].	In	particular,	cruciferous	
vegetables	and	citrus	fruits	show	favourable	outcomes	[46–48].	Limitations	of	
these	studies	include	publication	bias	(small	studies),	recall	bias,	(self-reported),	
and	heterogeneity	of	“food	dose”	levels.	
	
3.2.3.5.	Meat	
Within	our	dataset,	two	case-control	studies	found	an	association	of	processed	
meats	and	animal	protein	with	BC.	The	concern	arises	from	the	possible	
presence	of	nitroso	compounds	in	processed	meat,	but	the	finding	requires	
additional	confirmation	[49–51].	
	
3.2.3.6.	Diet	diversity	
A	balanced	and	“Mediterranean	diet”	has	been	assessed	through	the	EPIC	study	
and	large	case-control	studies	using	consumption	questionnaires	for	specific	
food	items,	but	the	results	have	been	inconclusive	[52,53].	
	
3.2.4.	Environmental	carcinogens	
3.2.4.1.	Arsenic	
Exposure	to	arsenic	in	drinking	water	is	a	recognised	cause	of	BC	[54–56].	The	
largest	study	in	our	series	(a	systematic	review	of	40	studies	and	a	meta-analysis	
of	17	studies)	showed	a	risk	effect	of	2.7	(95%	CI	1.2–4.1)	for	10	µg/l	and	5.8	
(2.9–8.7)	for	140	µg/l.	Limitations	included	exposure	misclassifications	between	
studies,	which	restricted	greater	data	pooling	[57].	Interestingly,	a	case-control	
study	found	that	people	who	are	poor	at	methylating	inorganic	arsenic	are	at	
higher	risks	of	BC	[58].	
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3.2.4.2.	Nitrates/selenium/cadmium	
In	our	series,	a	meta-analysis	of	five	studies	(mixed	cohort/case-control)	showed	
no	difference	from	exposure	to	nitrate-containing	drinking	water	[59],	but	
additional	studies	are	needed.	A	randomised	controlled	trial	(RCT)	secondary	
analysis	with	a	median	follow-up	of	7.1	yr	demonstrated	no	protective	effect	of	
selenium	on	BC	risk	[60].	
	
3.2.4.3.	Nuclear	power	plant	and	shale	gas	extraction	
An	ecologic	study	[61]	found	a	statistically	significant	RR	of	BC	in	persons	living	
inside	20	km	from	a	nuclear	power	plant	(RRmen	1.08	[95%	CI	1.00–1.17],	
RRwomen	1.19	(95%	CI	1.02–1.39]).	However,	the	study	used	proximity	as	a	
proxy	for	exposure	and	did	not	assess	blood	profiles.	Similarly,	an	observational	
study	showed	increased	BC	rates	in	areas	of	shale	gas	drilling,	but	the	study	had	
limited	confounder	control	and	small	populations	[62].		
	
3.2.4.5.	Routine	personal	hair	dye	use	
A	meta-analysis	of	15	case-control	and	two	cohort	studies,	involving	617	937	
persons	[63],	showed	a	pooled	RR	for	BC	of	0.93	(0.82–1.05)	for	ever	use	and	
1.29	(0.98–1.71)	for	use	of	dark-coloured	dyes.	
	
3.2.5.	Gender,	race,	and	socioeconomic	factors	
3.2.5.1.	Gender	
Reasons	for	sex	differences	in	BC	incidence	and	survival	(higher	in	males)	are	
thought	to	be	related	to	a	few	(likely	in	combination)	factors	such	as	differences	
in	access	to	health	care,	delayed	diagnosis	(haematuria	or	lower	urinary	tract	
symptoms	being	attributed	to	cystitis	in	women),	occupational	exposures,	and	
smoking	patterns	[8].	Potential	molecular	mechanisms	include	disparate	
metabolic	detoxification	of	carcinogens	and	difference	in	the	sex	steroid	
hormone	pathways	[64].	
	
3.2.5.2.	Hormonal	and	reproductive	factors	
A	cohort	study	showed	that	parous	women	had	a	lower	incidence	of	BC	
compared	with	nulliparous	women	(IRR	0.80,	95%	CI	0.72–0.89).	Absence	of	
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data	on	menstrual	history,	use	of	exogenous	hormones,	and	smoking	were	
important	limitations	within	this	study	[65].		
	
3.2.5.3.	Race	
More	historical	Surveillance	Epidemiology	and	End	Results	(SEER)	data	from	the	
USA	suggested	that	black	people	have	a	lower	incidence	but	higher	mortality.	
Explanations	for	higher	mortality	include	lack	of	access	to	health	care	and	
advanced	disease	at	presentation	[66].	
	
3.2.5.4.	Socioeconomic	status	
In	the	USA,	BC	was	related	to	those	receiving	Medicaid	health	benefits	[67].	
These	factors	may	be	surrogate	markers	for	urban	living	[68],	smoking,	and	
occupational	risk.		
	
3.2.6.	Gene-environment	interaction	
The	genetic	basis	of	BC	is	gaining	increased	attention	and	evidence.	The	Cancer	
Genome	Atlas	provided	comprehensive	molecular	characterisation	of	MIBC	
based	on	somatic	changes	(eg,	increased	somatic	copy	number	of	FGFR3	and	
KRAS	genes),	but	most	of	these	represent	acquired	and	not	inherited	mutations	
[69].	The	role	of	germline	genetic	polymorphisms	in	increasing	BC	susceptibility	
in	persons	exposed	to	carcinogens	is	established.	Here,	we	investigated	gene-risk	
factor	interactions	for	the	main	attributable	factors.	
	
3.2.6.1.	Occupation-gene	interactions	and	BC	risk	
The	main	polymorphisms	associated	with	BC	involve	two	carcinogen-
detoxification	genes—NAT2	and	GSTM1—since	abnormalities	in	these	genes	
leads	to	longer	exposure	to	carcinogens.	Links	with	N-acetyltransferase	2	
(NAT2)	acetylation	status	and	GSTM1	copy	number	are	well	documented	to	be	
associated	with	the	risk	of	BC.	Our	series	reports	on	recent	studies	that	have	
added	to	this	field.	Figueroa	et	al	[70]	examined	whether	established	common	
single-nucleotide	polymorphisms	(SNPs),	which	have	been	associated	with	BC	
risk	from	candidate	gene	studies	or	genome-wide	association	studies	(GWAS),	
modify	the	association	between	employment	in	high-risk	occupations	and	BC,	
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using	data	from	the	New	England	Bladder	Cancer	Study	and	the	Spanish	BC	
Study.	It	was	observed	that	three	BC	susceptibility	variants	displayed	statistically	
significant	evidence	of	additive	interactions,	specifically	the	GSTM1	deletion	
polymorphism,	rs11892031	(UDP	glucuronyltransferase	1A	[UGT1A]),	and	
rs798766	(TMEM129-TACC3-FGFR3).		
In	a	case-control	study,	patients	were	genotyped	for	polymorphisms	in	NAT2,	
GSTM1,	GSTT1,	UGT1A,	rs9642880	(close	to	c-MYC),	and	rs710521	(close	to	
TP63)	in	relation	to	occupational	BC	[71].	Increased	risks	were	seen	with	GSTM1	
(in	individuals	exposed	to	aromatic	amines	and	carbolineum,	painters,	and	
varnishers)	and	UGT1A	(in	individuals	exposed	to	carbolineum,	crack	test	spray,	
and	PAH,	and	in	painters	and	varnishers).	In	another	case-control	study,	null	or	
low-activity	genotypes	of	the	GSTA1,	T1,	and	P1	did	not	contribute	
independently	towards	the	risk	of	BC	in	males	[72].	However,	in	association	with	
occupational	exposure,	low-activity	GSTA1	and	GSTM1-null	as	well	as	GSTT1-
active	genotypes	increase	individual	susceptibility.	GSTM1-null	genotype	was	
over-represented	among	cases	(OR	2.1,	95%	CI	1.1–4.2).	Low-activity	GSTA1	
genotype	and	GSTM1-	and	GSTT1-active	patients	showed	an	enhanced	BC	risk	
among	individuals	exposed	to	solvents	and	pesticides	(GSTT1	active).	Pesch	et	al	
[73]	used	data	from	the	EPIC	study	to	show	that	occupational	exposure	to	
aromatic	amines	and	PAH	was	associated	with	an	increased	BC	risk	(OR	1.37,	
95%	CI	1.02–1.84,	and	OR	1.50,	95%	CI,	1.09–2.05,	respectively).	NAT2	slow	
acetylation	did	not	modify	these	risk	estimates.		
A	multicentre	case-control	study	examined	associations	between	pesticide	
exposure,	genetic	polymorphisms	for	NQO1	and	SOD2,	and	BC	risk	among	male	
agricultural	workers.	There	was	an	increased	BC	risk	among	participants	with	
combined	genotypes	for	low	NQO1	and	high	SOD2	(RR	2.14	[95%	CI	1.19–3.85])	
activities	[74].	
	
3.2.6.2.	Smoking-gene	interactions	and	BC	risk	
The	most	convincing	contemporary	data	are	derived	from	two	GWAS.	These	are	
observational	studies	that	assess	traits	between	a	genome-wide	set	of	variants	
and	human	disease.	A	meta-analysis	by	Garcia-Closas	et	al	[75]	included	a	total	of	
3942	cases	and	5680	controls	of	European	background	in	seven	studies	
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participating	in	the	National	Cancer	Institute	(NCI)	GWAS.	This	analysis	
evaluated	12	SNPs	previously	identified	as	susceptibility	variants.	Six	of	12	
variants	showed	significant	additive	gene-smoking	(ever	vs	never)	interactions:	
8p22	NAT2,	2q37.1	UGT1A6,	1p13.3	GSTM1,	8q24.3	PSCA,	8q24.21	(MYC),	
22q13.1	CBX6	APOBEC3A.	NAT2	was	also	the	only	variant	to	show	significant	
multiplicative	gene-smoking	interactions.	A	similar	pattern	was	seen	when	
comparing	current	and	former	smokers	with	never	smokers,	but	weaker	
evidence	for	interactions	was	found	when	comparing	current	with	former	
smokers.	This	study	was	limited	by	the	use	of	a	“weighted	allele”	approach,	
which	is	a	summary	measure	of	weights	for	each	allele	related	to	a	risk	factor.	
Selinski	et	al	[76]	addressed	this	by	pooling	data	(IFADo-NBCS	groups)	and	cited	
four	variant	combinations	associated	with	BC:rs1014971[AA]	near	
apolipoprotein	B	mRNA	editing	enzyme,	catalytic	polypeptide-like	3A	
(APOBEC3A)	and	chromobox	homolog	6	(CBX6),	solute	carrier	family	1s4	(urea	
transporter),	member	1	(Kidd	blood	group;	SLC14A1)	exon	SNP	rs1058396[AG,	
GG],	UDP	glucuronosyltransferase	1	family,	polypeptide	A	complex	locus	
(UGT1A)	intron	SNP	rs11892031[AA],	and	rs8102137[CC,	CT]	near	cyclin	E1	
(CCNE1).	
Figueroa	et	al	[77]	conducted	a	GWAS	based	on	primary	scan	data	from	the	NCI	
BC	GWAS	(including	2422	BC	cases	and	5751	controls)	and	showed	an	
association	between	smoking	and	BC	risk;	rs1711973	(FOXF2)	on	6p25.3	was	a	
susceptibility	SNP	for	never	smokers	(OR	1.34,	95%	CI	1.20–1.50)	and	
rs12216499	(RSPH3-TAGAP-EZR)	on	6q25.3	was	a	susceptibility	SNP	for	ever	
smokers	(OR0.75,	95%	CI	0.67–0.84).	However,	in	an	updated	analysis	by	the	
same	group	using	a	larger	dataset,	no	evidence	was	found	for	these	associations.	
Genome-wide	significance	was	found	for	rs6104690	(gene-desert)	and	
rs4907479	(MCF2L)	[78].	
A	meta-analysis	of	26	case-control	studies	assessed	the	association	between	
variations	in	the	x-ray	repair	cross-complementing	group	1	(XRCC1)	DNA	repair	
gene,	smoking,	and	BC	[79].	Results	suggested	that	the	XRCC1	R399Q	
polymorphism	might	play	a	protective	role	against	BC	among	smokers.	
Associations	have	also	been	seen	for	the	XRCC6	gene	[80],	but	not	for	XRCC3	
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[81].	Polymorphisms	in	the	VEGF	gene	were	also	shown	to	have	associations	
with	BC	and	smoking	in	two	NRT	[82,83].	
	
3.3.	Medical	conditions	and	treatments	
3.3.1.	Diabetes	mellitus	
The	largest	meta-analysis	included	36	(nine	case-control	and	27	cohort)	studies	
and	showed	an	increased	RR	of	BC	in	diabetes	mellitus	(DM;	pooled	RR	1.35,	
95%	CI	1.17–1.56).	The	RR	of	BC	was	negatively	correlated	with	the	duration	of	
DM,	with	the	higher	risk	of	BC	found	among	patients	diagnosed	within	<5	yr	
[84].	However,	this	meta-analysis	suffered	from	significant	heterogeneity	in	
study	design	and	adjustment	for	confounders.		
	
3.3.2.	Thiazolidinedione	use	
Two	large	meta-analyses	have	shown	statistically	significantly	increased	risks	of	
BC	with	the	oral	antidiabetic	agent	pioglitazone.	Subgroup	analysis	showed	the	
risk	of	BC	to	be	greatest	with	>28.0	g	daily	of	pioglitazone	[85,86].	
However,	the	first	cohort	study	to	assess	long-term	use	of	pioglitazone	(based	on	
up	to	16	yr	of	follow-up)	demonstrated	no	increased	risk	of	BC,	although	the	
authors	concluded	that	they	could	not	exclude	an	association	[87].	
	
3.3.3.	Metformin,	sulphonylurea,	and	insulin	
A	large	cohort	study	demonstrated	a	reduced	risk	of	BC	with	the	use	of	oral	
antidiabetic	agents	metformin	and	sulphonylurea	[88].	With	regard	to	insulin,	
the	largest	cohort	study	found	no	association	with	BC	risk	[89].	
	
3.3.4.	Systemic	lupus	erythematosus	
A	meta-analysis	of	seven	studies	showed	a	pooled	RR	of	2.11	(95%	CI	1.12–3.99)	
for	BC	risk	[90].	However,	there	were	confounding	factors	such	as	the	use	of	
cytotoxic	drugs	and	coexistence	of	overlapping	syndromes.	Similar	findings	were	
seen	for	systemic	sclerosis	[91]	and	inflammatory	bowel	disease	[92].	
	
3.3.5.	Anthropometric	measures/physical	activity	
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Sun	et	al	[93]	reported	pooled	RRs	of	BC	of	1.07	(95%	CI	1.01–1.14)	and	1.10	
(1.06–1.14)	for	overweight	and	obesity,	respectively.	Body	mass	index	(BMI)	was	
associated	with	BC	risk	in	a	linear	fashion,	and	the	risk	increased	by	4.2%	for	
each	5	kg/m2	increase.	A	limitation	is	that	higher	BMIs	are	likely	to	be	associated	
with	other	unhealthy	behaviours	such	as	lower	physical	activity	levels	and	
poorer	diet.	However,	data	across	studies	are	conflicting	[94].	
	
3.3.6.	Analgesics	
A	meta-analysis	of	17	(eight	cohort	and	nine	case-control)	studies	showed	that	
paracetamol	and	aspirin	were	not	associated	with	BC	risk	(or	reduction).	
However,	the	use	of	nonaspirin	nonsteriodal	anti-inflammatory	drugs	was	
significantly	associated	with	a	43%	reduction	in	BC	risk	among	nonsmokers	(RR	
0.57,	95%	CI	0.43–0.76),	but	not	among	current	smokers	[43,95].			
	
3.3.7.	Statins	
A	meta-analysis	of	13	(three	RCT	and	10	observational)	studies	showed	a	
nonsignificant	increase	in	BC	risk	amongst	statin	users	(RR	1.07,	95%	CI	0.95,	
1.21)	[96].	
	
3.3.8.	Radiation	
Radiotherapy	(RT)	to	treat	cancers	of	the	ovary,	testis,	cervix,	uterus,	and	
prostate,	and	non-Hodgkin	lymphoma	has	been	associated	with	developing	
second	malignancies	of	the	bladder.	In	a	meta-analysis	of	21	studies	looking	at	
radiation	of	the	prostate,	BC	risk	was	elevated	with	a	hazard	ratio	(HR)	of	1.67	
(95%	CI	1.55–1.80)	[97].	In	a	retrospective	cohort	study	from	SEER	data,	Abern	
et	al	[98]	found	an	RR	of	1.7	for	RT-treated	prostate	cancer	(PC;	95%	CI	1.57–
1.86).	All	forms	of	RT	showed	an	elevated	risk,	with	the	greatest	risk	at	>10	yr	
lag.	Older	age	at	diagnosis	was	associated	with	increased	BC	risk,	and	nonwhite	
race	reduced	risk.	Histologically,	the	number	of	non–urothelial	cell	carcinoma	
tumours	was	greater	than	usual	and	carcinoma	in	situ	was	more	common.	
Anatomically,	BCs	were	more	frequently	found	at	the	trigone.	Interestingly,	stage	
and	grade	at	diagnosis	did	not	differ	with	prior	radiation,	and	a	nonsignificant	
increase	in	lymph	node	positivity	was	found.	However,	when	controlled	for	
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competing	risk	(PC),	cumulative	hazard	curves	revealed	that	patients	had	30%	
increased	BC	mortality	if	previously	treated	with	radiation	[98].	
	
3.3.9.	Metabolic	syndrome	
A	case-control	study	demonstrated	that	patients	with	metabolic	syndrome	
reported	a	two-fold	increase	in	BC	risk	[99].		
	
3.3.10.	Recurrent	urinary	tract	infections	
A	case-control	study	showed	that	urinary	tract	infections	(UTIs)	were	associated	
with	an	increased	risk	of	BC	[100].	However,	two	studies	have	shown	a	
protective	effect	for	those	treated	with	antibiotics	for	the	UTI	[101].			
	
3.3.11.	Spinal	cord	injury	
A	large	cohort	study	(54	401	patients)	showed	no	significant	difference	in	risk	
(HR	0.91,	95%	CI	0.72–1.16)	[102].	Conversely,	a	smaller	study	on	1816	patients	
with	spinal	cord	injury	(SCI),	matched	with	patients	with	chronic	indwelling	
urinary	catheters	without	an	SCI	and	healthy	control	patients,	showed	a	higher	
risk	of	BC	among	those	with	SCI	(HR	6.51,	95%	CI	2.56–16.52)	[103].	However,	
these	papers	did	not	comment	on	tumour	cell	type.	
	
3.3.12.	Renal	transplant	
A	meta-analysis	of	11	retrospective	observational	studies	revealed	a	pooled	RR	
of	3.18	(95%	CI	1.34–7.53).	There	was	a	lack	of	adjustment	and	exclusion	of	BC	
prior	to	the	transplant	as	the	patients	were	not	screened	[104].	
	
4.	Conclusions	
BC	is	common,	and	a	significant	proportion	of	the	cases	are	attributable	to	
tobacco	use	as	well	as	occupational	and	environmental	factors	(Table	2	
summarises	the	best-known	risk	factors).	
Incidence	patterns	and	trends	are	dependent	on	changes	in	smoking	behaviour	
and	shifting	occupational	and	environmental	regulations,	such	as	workplace	
sanctions	on	known	or	suspected	carcinogens.	The	evidence	is	growing	for	the	
role	of	genetic	susceptibility	and	interplay	with	other	risk	factors.		
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One	of	the	problems	with	the	identification	and	quantification	of	BC	risk	factors	
is	the	heterogeneous	phenotype	of	the	disease.	For	the	future,	it	will	be	
important	to	arrive	at	standardised	subclassifications	of	BC	and	stratify	analyses	
according	to	these	subtypes.	
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Fig. 1 – CONSORT diagram. Search captured all articles from 1 May 2012 until 9 
April 2018. BC = bladder cancer. 
!
Fig. 2 – International variation in estimated age-standardised bladder cancer 
incidence rates in (A) men and (B) women [2]. Age-standardised rates (ASR; world 
standard population) per 100 000. 
!
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Fig. 3 – International variation in estimated age-standardised bladder cancer 
mortality rates in (A) men and (B) women [2]. Age-standardised rates (ASR; world 
standard population) per 100 000. 
!
Fig. 4 – Estimated annual percent change in (A) age-standardised incidence and (B) 
mortality rates of bladder cancer in men (top) and women (bottom) in selected 
countries (last 15 yr of available data). Regional incidence data from Gharbiah 
(Egypt); Blantyre (Malawi); Harare (Zimbabwe); Kampala (Uganda); Antofagasta 
(Chile);Villa Clara (Cuba); Cali (Colombia); Quito (Ecuador); SEER (USA); Alberta, 
British Columbia, Manitoba, Northwest Territories, New Brunswick, Nova Scotia, 
Prince Edward Island, Newfoundland and Labrador, Ontario, and Saskatchewan 
(Canada); Miyagi, Nagasaki, and Osaka (Japan); Hong Kong and Shanghai (China); 
Chiang Mai (Thailand); Manila (Philippines); Chennai and Mumbai (India); Izmir 
(Turkey); Riyadh (Saudi Arabia); Cracow City, Kielce, and Lower Silesia (Poland); St 
Petersburg (Russian Federation); Granada, Murcia, Navarra, and Tarragona (Spain); 
City of Torino, Modena, Parma, Romagna, Ragusa, and Varese provinces (Italy); 
Geneva and St. Gall-Appenzell (Switzerland); Berlin, Brandenburg, Mecklenburg, 
Saxony, Saxony-Anhalt, Schleswig-Holstein, and Thuringia (Germany); Doubs, Isere, 
Haut-Rhin, Herault, and Tarn (France); and Australian Capital Territory, New South 
Wales, Northern Territory, Queensland, South Australia, Tasmania, Victoria, and 
Western Australia (Australia). Data from Cuba are presented with Central and 
South America. a A change significantly different than 0. Reproduced from Antoni 
S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence 
and mortality: a global overview and recent trends. Eur Urol 2017;71:96–108 [1]. 
	
	
Table	1	–	Number	of	reports	by	section	
Subject	 Number	of	articles	included	in	review	
Incidence	and	mortality	patterns	 6	
Tobacco	smoking	 15	
Occupational	carcinogen	exposure	 20	
Dietary	associations	 29	
Medical	disease	and	treatments	 91	
Environmental	carcinogen	exposure	 23	
Genetic	associations	 87	
Gender,	socioeconomic	group,	and	racial	differences	 8	
	
	 	
Table	2	–	BC	risk	factor	summary	
Risk	factors	for	bladder	cancer	summary	
Tobacco	smoking	
Occupations	
• Aluminium	production		
• Rubber	production	industry	
• Dye	industry	
• Coal-tar	pitch	a	
• Dry	cleaning	a	
• Hairdressers	and	barbers	a	
• Printing	a	
• Textile	manufacturing	a	
Occupational	carcinogens	
• 2-Naphthylamine	
• Benzidine	
• 4-aminobiphenyl	
• 4,4′-methylene-bis	(2-chloroaniline)	
• Ortho-toluidine	
• Metal	working	fluids	a	
• Tetrachloroethylene	a	
• Diesel	exhaust	a			
• Polyaromatic	hydrocarbons	a	
• Combustion	and	pyrolysis	products	from	natural	gas	a	
Dietary	factors		
• Low	hydration	a	
• Low	intake	of	citrus	fruit,	cruciferous	vegetables,	
vitamin	A,	folate,	and	vitamin	D	a	
• Processed	meat	and	animal	protein	a	
Environmental	factors		
• Arsenic	and	inorganic	arsenic	compounds	
• Disinfection	by-products	a	
• Nitrates	a	
Age	
• Median	age	at	diagnosis	is	73	yr	
Race	
• White	race	
	
BC	=	bladder	cancer;	NSAID	= nonsteroidal	anti-inflammatory	drugs.	
a	Suspected	risk	factors.	
Gender	
• Male	sex	
• Hormone	and	reproductive	factors	a	
Socioeconomic	status	
• Industrialised	regions	
Medical	disease	
• Radiotherapy	
• Schistosomiasis	
• NSAIDs	(reduced	risk)	
• Cyclophosphamide	
• Phenobarbital	(reduced	Risk)	
• Pioglitazone	a	
Family	history	of	bladder	cancer	
 
Search	Terms:		((Bladder	cancer	[MeSH	terms]	and	incidence	[MeSH	terms])	(OR)	(Bladder	
cancer	[MeSH	terms]	and	prevalence	[MeSH])	(OR)	(Bladder	cancer	[MeSH	terms]	and	
risk)	(OR)	(Bladder	cancer	[MeSH	terms]	and	risk	factor	[MeSH	terms])	(OR)	Bladder	cancer	
[MeSH	terms]	and	hazard)).Primary	search	N=2159.	Second	search	N=32.	Total	=	2191	
Full	manuscripts	assessed	for	
eligibility	(n=446)	
Duplicates	removed	(n=3)	
Abstracts	assessed	for	eligibility	
(n=2188)	
Non-eligible	studies	excluded	(n=1742)		
Non-eligible	studies	excluded	(n=184) 	 		
	 	110		GeneTcs	
	 	19		Not	incidence	or	risk	of	developing	BC	
	 	19		Review	arTcle	(non-systemaTc)	
	 	19		Unable	to	access	full	manuscript	
	 	8		Single	country	incidence	data	
	 	6		Basic	science	arTcle	
	 	2		Insuﬃcient	paTents	
	 	1		DuplicaTon	of	paTent	populaTon		Full-text	manuscripts	
included	(n=279)	
Figure	1.	CONSORT.	Search	captured	all	arTcles	from	May	1st	2012	unTl	9th	April	2018	.		
Searched	
references		
(n=17)	
Figure 1
Figure	legends	
	
Figure	2:	Interna.onal	varia.on	in	es.mated	age-standardised	bladder	cancer	incidence	rates	(a)	in	men;	(b)	in	women	(2).	Age-
standardised	rates	(ASR,	World	Standard	Popula.on)	per	100,000	
		
Figure	3:	Interna.onal	varia.on	in	es.mated	age-standardised	bladder	cancer	mortality	rates	(a)	in	men;	(b)	in	women	(2).	Age-
standardised	rates	(ASR,	World	Standard	Popula.on)	per	100,000	
		
Figure	4:	Es.mated	annual	percent	change	in	age-standardised	incidence	(leK)	and	mortality	(right)	rates	of	bladder	cancer	in	
men	(top)	and	women	(boMom)	in	selected	countries	(last	15	year	of	available	data).	Reproduced	from	Antoni	S,	et	al.	Bladder	
Cancer	Incidence	and	Mortality:	A	Global	Overview	and	Recent	Trends.	Eur	Urol.	2017;71(1):96-108	(1).	
Regional	incidence	data	from	Gharbiah	(Egypt),	Blantyre	(Malawi),	Harare	(Zimbabwe),	Kampala	(Uganda),	Antofagasta	(Chile),	
Villa	Clara	(Cuba),	Cali	(Colombia),	Quito	(Ecuador),	SEER	(USA),	Alberta,	Bri.sh	Columbia,	Manitoba,	Northwest	Territories,	New	
Brunswick,	Nova	Sco.a,	Prince	Edward	Island,	Newfoundland	and	Labrador,	Ontario,	and	Saskatchewan	(Canada),	Miyagi,	
Nagasaki,	and	Osaka	(Japan),	Hong	Kong	and	Shanghai	(China),	Chiang	Mai	(Thailand),	Manila	(Philippines),	Chennai	and	Mumbai	
(India),	Izmir	(Turkey),	Riyadh	(Saudi	Arabia),	Cracow	City,	Kielce,	and	Lower	Silesia	(Poland),	St	Petersburg	(Russian	Federa.on),	
Granada,	Murcia,	Navarra,	and	Tarragona	(Spain),	City	of	Torino,	Modena,	Parma,	Romagna,	Ragusa,	and	Varese	provinces	(Italy),	
Geneva	and	St.	Gall-Appenzell	(Switzerland),	Berlin,	Brandenburg,	Mecklenburg,	Saxony,	Saxony-Anhalt,	Schleswig-Holstein,	and	
Thuringia	(Germany),	Doubs,	Isere,	Haut-Rhin,	Herault,	and	Tarn	(France),	Australian	Capital	Territory,	New	South	Wales,	
Northern	Territory,	Queensland,	South	Australia,	Tasmania,	Victoria,	and	Western	Australia	(Australia).	Data	from	
Cuba	are	presented	with	Central	and	South	America.	
a	A	change	signiﬁcantly	diﬀerent	than	0.	
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